A novel MSC-based immune induction strategy for ABO-incompatible liver transplantation: a phase I/II randomized, open-label, controlled trial

ABO-incompatible liver transplantation (ABO-i LT) has become a rescue therapeutic option for patients with severe hepatic failure. Although the use of rituximab greatly reduces the morbidity of antibody-mediat...

Source: Stem Cell Research and Therapy - April 16, 2021 Category: Stem Cells Authors: Yingcai Zhang, Jiebin Zhang, Huimin Yi, Jun Zheng, Jianye Cai, Wenjie Chen, Tongyu Lu, Liang Chen, Cong Du, Jianrong Liu, Jia Yao, Hui Zhao, Guoying Wang, Binsheng Fu, Tong Zhang, Jian Zhang & hellip; Tags: Research Source Type: research